Spotlight On... Amgen deploys West Pharma vials to store its injectable cancer med Imlygic; Drug delivery-focused Amplyx Pharmaceuticals raises $50M; FDA clears topical skin adhesive for wound closure; and more...

As drugs arrive in ever more formulations and the complexity of their ingredients increases, the demand for advanced storage solutions increases. Amgen ($AMGN) announced that it is deploying West Pharmaceutical Services' Daikyo Crystal Zenith vials to store its injectable, FDA-approved med Imlygic for recurrent melanoma. The vials can withstand cold storage requirements, and reduce the risk of breakage that exists with glass. "West recognizes the growing demand for high quality and technologically advanced containment systems for today's sophisticated biologic drugs, particularly when there may be challenges of interaction or adsorption related to traditional glass vials," said West Pharma senior vice president and chief technology officer John Paproski, in a statement. "Daikyo Crystal Zenith technology represents an important way to address the needs of our customers in this growing biotechnology market." More

> JLABS company Amplyx Pharmaceuticals increased its Series B haul to $49.5 million due to the participation of 3X5 Partners. The company is developing its small molecule anti-infective candidate in both oral and intravenous formulations to address the need for hospital administration and convenient usage after discharge. More

> Alpharetta, GA's Chemence Medical announced FDA clearance of its drug/device topical skin adhesive for wound closure. More

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.